Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peg GCSF in Acute on Chronic Liver Failure Survivors
NCT02788240Terminated
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- May 2016
- Primary completion
- Jul 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial in acute-on-chronic liver failure (ACLF) comparing Peg GCSF + SMT with Placebo + SMT (2 arms). Primary endpoint: Transplant-free survival at 1 year. Started May 2016; status: terminated.
02
Drugs
Peg GCSF
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT02788240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02788240.